Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors

Further Publications Immunology

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Lancet

Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP

doi: 10.1016/S0140-6736(24)01774-4

Melanoma and Skin Cancer

Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy

Melanoma Res

Asher N, Bar-Hai N, Ben-Betzalel G, Stoff R, Grynberg S, Schachter J, Frommer-Shapira R

doi: 10.1097/CMR.0000000000000985

Melanoma and Skin CancerFurther Publications Rheumatology

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma

J Autoimmun

Tenstad HB, Ruhlmann CH, Möller S, Kjaer S, Bastholt L, Just SA, Lindegaard H

doi: 10.1016/j.jaut.2025.103400

Further Publications Immunology

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Acta Derm Venereol

Juan-Carpena G, Martínez Banaclocha N, Palazón Cabanes JC, Niveiro-de Jaime M, Betlloch Mas I, Blanes-Martínez M

doi: 10.2340/actadv.v105.42023

Melanoma and Skin Cancer

Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort

Melanoma Res

Macaire C, Lefevre W, Dalac S, Montaudié H, Legoupil D, Dereure O, Dutriaux C, Leccia MT, Aubin F, Grob JJ, Saiag P, De Quatrebarbes J, Maubec E, Lesimple T, Granel-Brocard F, Mortier L, Dalle S, Lebbé C, Prod'homme C

doi: 10.1097/CMR.0000000000000973

Further Publications Immunology

Haematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study

J Eur Acad Dermatol Venereol

Bejarano L, Grau-Pérez M, Paíno-Román M, Muret MPG, Morillo M, Muniesa C, Torre-Castro J, Estrach MT, Díez EA, Belloso RML, Peñate Y, Martínez-Mera C, Botella-Estrada R, Eceiza MJM, Ortiz Romero PL, Blanes M, Fernández-de-Misa R, Prieto-Torres L, Amer MEP, Iznardo H, Moreno-Vílchez C, Servitje O, García-Doval I, Cañueto J

doi: 10.1111/jdv.20638

T CellsFurther Publications Dermatology

Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity

Nature

Faust Akl C, Andersen BM, Li Z, Giovannoni F, Diebold M, Sanmarco LM, Kilian M, Fehrenbacher L, Pernin F, Rone JM, Lee HG, Piester G, Kenison JE, Lee JH, Illouz T, Polonio CM, Srun L, Martinez J, Chung EN, Schüle A, Plasencia A, Li L, Ferrara K, Lewandrowski M, Strathdee CA, Lerner L, Quéva C, Clark IC, Deneen B, Lieberman J, Sherr DH, Antel JP, Wheeler MA, Ligon KL, Chiocca EA, Prinz M, Reardon DA, Quintana FJ

doi: 10.1038/s41586-025-08997-x

Melanoma and Skin Cancer

Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study

Acta Derm Venereol

Vitek L, Goronflot T, Dutriaux C, Deleuze A, Le Corre Y, Duval-Modeste AB, Fresnard C, Jeudy G, Lamoureux A, Gaudy-Marqueste C, Legoupil D, Baroudjian B, L'Orphelin JM, Peuvrel L, Khammari A, Mortier L, Quereux G

doi: 10.2340/actadv.v104.41297

Melanoma and Skin Cancer

A comparative study of Merkel cell carcinoma and melanoma incidence and survival in the United States, 2000-2021

J Invest Dermatol

Tribble JT, Brownell I, Cahoon EK, Sargen MR, Shiels MS, Engels EA, Volesky-Avellaneda KD

doi: 10.1016/j.jid.2024.12.014

Related content

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort

Haematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study

Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity

Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study

A comparative study of Merkel cell carcinoma and melanoma incidence and survival in the United States, 2000-2021